Register entry

Miyoshi America, Inc.

Data as of · How to read this entry

Registered sites
2
Active NDC listings
24
Labeller names
5
Live patents
0
Countries
2
Base
United States
Authorisation

Registered operations

Active ingredient (API) manufacture2Labelling2Packaging2
Sites

Registered establishments

2
EstablishmentAddressRegistered forFEI / DUNS
MIYOSHI EUROPE5 Rue Paul Rieupeyroux, Saint Priest, Auvergne 69800, France (FRA)Active ingredient (API) manufacture, Labelling, Packaging3010288733270759389
Miyoshi America, Inc.110 Louisa Viens Drive, P.O. Box 859, Dayville, Connecticut (CT) 06241, United States (USA)Active ingredient (API) manufacture, Labelling, Packaging3009481791161339692
Catalogue

Drug listings by form and route

24

24 active NDC listings: 24 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 24.

Dosage formNDCs
powder16
powder, for solution3
solution3
liquid1
solution, concentrate1
RouteNDCs
Labeller name on the listingNDCs
miyoshi america, inc.12
miyoshi america, inc6
miyoshi america inc.4
miyoshi america, inc.,1
miyoshi europe1
Catalogue

Marketed products

24
BrandGeneric nameForm / routeNDC
-TITANIUM DIOXIDEpowder76002-0002DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEpowder76002-0045DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEpowder76002-0046DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEsolution76002-0048DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEsolution, concentrate76002-0049DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEsolution76002-0051DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEsolution76002-0052DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEpowder76002-0054DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEpowder, for solution76002-0200DRUG FOR FURTHER PROCESSING
-TITANIUM DIOXIDEpowder, for solution76002-0300DRUG FOR FURTHER PROCESSING
-Titanium Dioxidepowder76002-0017DRUG FOR FURTHER PROCESSING
-Titanium Dioxidepowder76002-0055DRUG FOR FURTHER PROCESSING
-Titanium Dioxidepowder76002-0100DRUG FOR FURTHER PROCESSING
-Titanium Dioxidepowder76002-0110DRUG FOR FURTHER PROCESSING
-Titanium Dioxidepowder76002-0120DRUG FOR FURTHER PROCESSING
-Titanium Dioxidepowder76002-0130DRUG FOR FURTHER PROCESSING
-Titanium dioxidepowder87654-001DRUG FOR FURTHER PROCESSING
-ZINC OXIDEpowder76002-0400DRUG FOR FURTHER PROCESSING
-Zinc Oxidepowder, for solution76002-0140DRUG FOR FURTHER PROCESSING
-Zinc Oxidepowder76002-0401DRUG FOR FURTHER PROCESSING
-Zinc Oxideliquid76002-0500DRUG FOR FURTHER PROCESSING
-Zinc Oxidepowder76002-0600DRUG FOR FURTHER PROCESSING
-Zinc Oxidepowder76002-0700DRUG FOR FURTHER PROCESSING
-Zinc Oxidepowder76002-0800DRUG FOR FURTHER PROCESSING
Compare

Comparable companies in United States

Enquiry

Common questions

Is Miyoshi America, Inc. FDA approved?
Miyoshi America, Inc. holds 2 FDA-registered establishments across 2 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
Where are Miyoshi America, Inc.'s drugs manufactured?
At registered sites in France, the United States. The FDA register lists Saint Priest; Dayville, CT. Registered operations: active ingredient (API) manufacture, labelling, packaging.
What drugs does Miyoshi America, Inc. make?
24 products are listed under Miyoshi America, Inc. in the openFDA NDC Directory, most often as powder; powder, for solution; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.